Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 2/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403354 | 0.75 | MCHR1 (0.45) | HTR2CHTR2BMCHR1HRH3HRH1 | |
| SCHEMBL3282933 | 0.72 | PDE4A (0.34) | — | |
| SCHEMBL3278994 | 0.69 | IP6K1 (0.47) | HTR2CHTR2BMCHR1HRH3HRH1 | |
| SCHEMBL3274950 | 0.69 | HTR2C (0.53) | HTR2CHTR2BSLC6A4HTR6NEK2 | |
| SCHEMBL7254642 | 0.68 | MCHR1 (0.54) | HTR2CHTR2BMCHR1HRH3NPC1 | |
| SCHEMBL6031477 | 0.65 | CHRNA7 (0.49) | NPC1RAB9A | |
| SCHEMBL5140977 | 0.63 | CARM1 (0.66) | HTR2CHTR2BHRH3 | |
| SCHEMBL17554433 | 0.62 | MAOB (0.52) | HTR2CHTR2BMCHR1HRH3SLC6A4 | |
| SCHEMBL2286062 | 0.62 | HTR2C (0.68) | HTR2CHTR2BSLC6A4HTR6 | |
| SCHEMBL2283229 | 0.62 | HTR2C (1.00) | HTR2CHTR2BSLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | HTR2C 921/4885HTR2B 2229/4885MCHR1 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.